Ibogaine is a psychoactive substance that has various pharmacodynamic properties. The complete synthesis of Ibogaine treatment is elaborated in this article. When the Iboga therapy research was done on animals, it caused a reduction in morphine and heroin self-administration. It also caused a reduction in naloxone withdrawal signs. The Iboga alkaloid used in Ibogaine treatment can lead to the generation of addiction pharmacotherapy. Drug abuse is treated with Ibogaine in reliable and reputable treatment centres. This hallucinogenic substance can be used as a pharmacotherapy for drug addiction.
Pharmacodynamics of Ibogaine:
When we talk about the pharmacodynamics of Ibogaine treatment, we must know the fact that Ibogaine mainly affects various neurotransmitters in our brain or other body parts. It is used as an inhibitor for serotonin reuptake. The most potent inhibitor for Ibogaine treatment is Noribogaine. The mechanism of Ibogaine includes action like opioid receptor agonist or a partial organist. The activity of Ibogaine on the opioid receptors leads to an increase in the psychoactive effects. Ibogaine has hallucinogenic properties. Ibogaine also interacts with serotonin, acetylcholine, and dopamine systems. It also alters the normal functioning of proteins, including substance P, BDNF, etc.
Pharmacokinetics of Ibogaine:
Ibogaine is primarily found in the bark and roots of Tabernanthe Iboga. Many individuals use Ibogaine to overcome illnesses, hunger and it is also used in religious rituals. One dose can easily reduce the withdrawal of drugs in the patients. The pharmacokinetics of Ibogaine in Ibogaine therapy involves biotransformation of Ibogaine through CYP2D6. It is followed by the demethylation of Ibogaine, and as a result, Noribogaine is formed. If a single oral dose is administered to a patient, it may lead to complex or toxic pharmacokinetics effects. It shows detoxification in drug-dependent individuals. Ibogaine has a half-life of 2 hours. Hence, Ibogaine is formed from cytochrome P450 and then converted into Noribogaine. Noribogaine can also be called 12-hydroxyibogamine.
Chemistry of Ibogaine Used in Iboga Treatment:
2-iodo-4-metjoxyaniline reacts with triethylsilane to form 2-3-1H-indole. The synthesis reaction of Ibogaine is catalyzed by palladium acetate. The formed indole can be converted into 2-ethanol by N-iodosuccinamide. Then the formation of 2-iodo-3-1H-indole occurs, followed by the formation of 7-ethyl-2-azabicyclo-oct-5-ene. Then by the use of palladium acetate finally Ibogaine is synthesized. This Ibogaine is used in Ibogaine Treatment at various centres.
Morphine-induced dopamine release and morphine-induced hyperactivity are blocked by Ibogaine pretreatment. It enhances the effects of stimulants. Blockage of nicotine-induced dopamine release is also done by Ibogaine pretreatment. Binding of Ibogaine and Noribogaine occurs with kappa opioid and N-methyl-D-aspartate (NMDA) receptors. It also binds to serotonin uptake sites. This also binds to sigma-2 receptors. The kappa agonist and NMDA antagonist act on Ibogaine that produces effects on opioid and stimulant self-administration.
The serotonergic actions of Ibogaine are more considerable in the case of Ibogaine-induced reduction. Ibogaine-induced reduction is mediated by a nicotinic antagonist. Neurotoxic effects of Ibogaine are caused due to Sigma 2 antagonist. The effects of cocaine self-administration, morphine-induced hyperactivity, etc., are reduced by a kappa agonist or an NMDA antagonist. Many Ibogaine effects in Ibogaine treatment are reversed by the combined action of kappa agonist and NMDA. The slow release of Ibogaine from fat tissue can make it cause long-term effects. Various receptor combinations can affect Ibogaine interactions with different abusive drugs.